EyePoint Pharma - רווח נקי למניה אחת בשנים עשר החודשים האחרונים EYPT

The success of EyePoint Pharmaceuticals (EYPT) relies on regulatory verdicts regarding new drugs, as clearly demonstrated by the annual percentage change in EPS TTM. Currently, -39.50 represents the latest level value. EyePoint Pharmaceuticals (EYPT) aims to replace painful injections for AMD with the Durasert system, establishing a robust patent barrier through its unique microcapsule technology for sustained drug release.

This indicator captures the percentage change in net income per share over a rolling year, allowing investors to assess the actual profitability dynamics of the business. By analyzing the annual growth of EPS TTM, one can track the sensitivity of the market capitalization to the efficiency of the proprietary Durasert technology and the patent protection of new ophthalmological drugs, which determine the future financial results of EyePoint Pharmaceuticals (EYPT).